HLA Antibodies in Systemic Lupus Erythematosus
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 8, 2025
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into a specific issue faced by patients with systemic lupus erythematosus (SLE), an autoimmune disease. Patients with SLE can sometimes test positive for anti-HLA antibodies, which can lead to confusion when assessing their suitability for organ transplants. The trial aims to understand how common these false-positive results are in lupus patients and to evaluate new tests that could help prevent this issue, making it easier for patients to get the organ transplants they need.
To participate in this study, individuals must be adults who are being treated at the Amiens University Hospital and have systemic lupus erythematosus. They should not have any history of pregnancy, blood transfusions, or organ transplants, as these factors can increase the likelihood of having actual anti-HLA antibodies. Participants will not only contribute to important research but will also help improve the understanding and management of organ transplant compatibility for lupus patients. The trial is currently not yet recruiting participants, but it represents a significant step in enhancing care for those affected by this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients Adults
- • Followed in the internal medicine department of Amiens University Hospital - With systemic lupus erythematosus
- • Without HLA immunization risk factors (no history of pregnancy, transfusions or transplants)
- • With sera stored in the biobank
- Exclusion Criteria:
- • minor Patients
- • Opposing the re-use of their personal data for research purposes
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported